Literature DB >> 34022975

What next for a COVID-19 intellectual property waiver?

John Zarocostas.   

Abstract

Entities:  

Year:  2021        PMID： 34022975     DOI： 10.1016/S0140-6736(21)01151-X

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

1.  Protecting Intellectual Property While Satisfying Scientific Transparency.

Authors:  Thomas M Hemmerling; Ira S Hofer
Journal:  Anesth Analg       Date:  2022-07-05       Impact factor: 6.627

2.  Exploring the role of R&D collaborations and non-patent IP policies in government technology transfer performance: Evidence from U.S. federal agencies (1999-2016).

Authors:  Iman Hemmatian; Todd A Ponzio; Amol M Joshi
Journal:  PLoS One       Date:  2022-05-24       Impact factor: 3.752

3.  Charity or empowerment? The role of COVAX for low and middle-income countries.

Authors:  Felicitas Holzer; Tania Manríquez Roa; Federico Germani; Nikola Biller-Andorno; Florencia Luna
Journal:  Dev World Bioeth       Date:  2022-03-20       Impact factor: 2.427

Review 4.  Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?

Authors:  Gaurav Joshi; Pobitra Borah; Shweta Thakur; Praveen Sharma; Ramarao Poduri
Journal:  Hum Vaccin Immunother       Date:  2021-12-02       Impact factor: 3.452

Review 5.  Scaling Up the Global COVID-19 Vaccination Program: Production, Allocation, and Distribution with an Emphasis on Equity.

Authors:  Elaine M Louden
Journal:  Yale J Biol Med       Date:  2022-09-30

6.  Analyzing the Morality of Owning and Suspending Patent Rights for COVID-19 Vaccines in the Light of Catholic Social Teaching.

Authors:  Vivencio O Ballano
Journal:  Linacre Q       Date:  2021-12-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.